Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)
Stephen Walsh, William O Hahn, Wilton B. Williams, Ollivier Hyrien et autres
2 citationsmedRxiv
Jack Heptinstall
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
49Publications signalées
610Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
HIV Research and TreatmentHIV/AIDS drug development and treatmentMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches
Publications récentes
DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein
Stephen C. De Rosa, Ronnie M. Gravett, William O. Hahn, Manuel Villarán et autres
0 citationsVaccine
P-325. An Innovative Approach For An HIV-1 Prophylactic Vaccine – Results From A Phase I Clinical Trial
Pedro Garbes, Christina Chang, Howard Wright, Ryan Norton et autres
0 citationsOpen Forum Infectious Diseases
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Vimla Naicker, Philip Kotze, William Kilembe, Simpson Nuwamanya et autres
0 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nonhlanhla N. Mkhize, Bo Zhang, Caroline Brackett, Peter Elyanu et autres
1 citationNature Communications
Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320
Avi Kenny, Janine van Duijn, One Dintwe, Jack Heptinstall et autres
0 citationsEBioMedicine
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
K. Rachael Parks, Zoe Moodie, Mary Allen, Catherine Yen et autres
44 citationsScience Translational Medicine
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E. Seaton, Carmen A. Paez, Chenchen Yu, Shelly Karuna et autres
6 citationsThe Lancet HIV
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Cassie Grimsley Ackerley, Srilatha Edupuganti, Chenchen Yu, Alison C. Roxby et autres
2 citationsFrontiers in Immunology
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Zoe Moodie, Shuying Sue Li, Elena E. Giorgi, LaTonya D. Williams et autres
6 citationsEmerging Microbes & Infections
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Kathryn E. Stephenson, Cynthia L. Gay, Theresa Gamble, Lúcio Gama et autres
0 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, Zvavahera M. Chirenje et autres
3 citationsBMC Immunology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.